Bella Center in Copenhagen, Denmark, site of the 21st Congress of the European Hematology Association, which took place June 9-12, 2016.

Drug enables transfusion independence in lower-risk MDS

Uwe Platzbecker, MD

Results from a pair of phase 2 trials suggest luspatercept can produce erythroid responses and enable transfusion independence in patients with lower-risk myelodysplastic syndromes (MDS). In a 3-month base study, 51% of patients treated with luspatercept had an erythroid response, and 35% achieved transfusion independence. In an ongoing extension study, 81% of... [Read Article]

Stopping TKI therapy can be safe, study suggests

Johan Richter, MD, PhD

Results of a large study suggest that stopping treatment with tyrosine kinase inhibitors (TKIs) can be safe for patients with chronic myeloid leukemia (CML) in deep molecular response (MR4). Six months after patients stopped receiving a TKI, the relapse-free survival was 62%. At 12 months, it was 56%. Having a longer... [Read Article]

Site of major bleeding differs with NOACs and VKAs

Laura Franco, MD

Results of a new study suggest that vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs) can both confer an increased risk of major bleeding, but the type of bleeding tends to differ with the type of anticoagulant. The research showed that patients taking VKAs were more likely to be hospitalized for... [Read Article]

Platelet transfusion deemed ‘harmful’ in patient group

Attendees at the 21st
Congress of the European
Hematology Association

Results of the phase 3 PATCH trial suggest that platelet transfusions are not beneficial and can actually cause harm in patients with intracerebral hemorrhage (ICH) associated with antiplatelet therapy. The study showed that the odds of death or dependence at 3 months... [Read Article]

Drug can address unmet need in cHL, doc says

Anas Younes, MD

The PD-1 checkpoint inhibitor nivolumab can address an unmet need in patients with classical Hodgkin lymphoma (cHL) who have progressive or relapsed disease, according to a speaker at the 21st Congress of the European Hematology Association. In the phase 2 Checkmate-205 trial, nivolumab produced an objective response rate of 66% in cHL... [Read Article]

Immunotherapy ‘outcompetes’ chemo in rel/ref B-ALL

Max S. Topp, MD

Interim results from the phase 3 TOWER trial suggest blinatumomab can prolong overall survival (OS) when compared to standard care in adults with Ph-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). The median OS for patients treated with blinatumomab was nearly double the median OS of patients who received standard chemotherapy... [Read Article]

ESA benefits lower-risk MDS patients

Uwe Platzbecker, MD

The erythropoiesis-stimulating agent (ESA) darbepoetin alfa can provide a clinical benefit in patients with lower-risk myelodysplastic syndromes (MDS), a phase 3 trial suggests. In the ARCADE trial, darbepoetin alfa significantly reduced the incidence of red blood cell (RBC) transfusions in patients with low- and intermediate-1 risk myelodysplastic syndrome (MDS), when compared to... [Read Article]

A new standard of care for relapsed/refractory MM?

Meletios A. Dimopoulos, MD

The combination of daratumumab, lenalidomide, and dexamethasone (DRd) could become a new standard of care for patients with relapsed or refractory multiple myeloma (MM), according to a speaker at the 21st Congress of the European Hematology Association. In the phase 3 POLLUX study, DRd conferred the highest response rate reported to... [Read Article]

Inotuzumab bests standard of care in adult ALL

Hagop M. Kantarjian, MD
Photo courtesy of MDACC

In multiple categories, the antibody-drug conjuagate inotuzumab ozogamicin achieved significantly better results than the standard of care in the treatment of adults with acute lymphoblastic leukemia (ALL). Patients in the inotuzumab arm experienced a higher rate of complete remissions, a greater frequency of achieving minimal residual disease... [Read Article]